18/07/2022
07/07/2022
24/06/2022
09/06/2022
16/05/2022
24/04/2022
16/03/2022
01/12/2021
31/05/2021
26/05/2021
12/02/2021
EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
29/01/2021
EuropaBio welcomes the European Health Union plan. The EU has indeed a critical role to play in public health and better crisis preparedness to address serious cross-border health threats and improving crisis management capacity.
20/01/2021
Read our submission to the European Commission’s Inception Impact Assessment titled “Revision of the EU legislation on medicines for children and rare diseases“.
24/12/2020
30/11/2020
Call for more effective EU regulation of clinical trials with Advanced Therapy
Medicinal Products consisting of or containing Genetically Modified Organisms
20/10/2020
EuropaBio Position Paper on the use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making.
19/10/2020
EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
30/09/2020
EuropaBio Patient engagement with the European Medicines Agency
13/08/2020
Read our Statement in response to the publication of the European Commission’s evaluation of the Orphan and Paediatric Regulations.
03/08/2020
Health industry sectors, representing pharmaceutical and medical technology companies welcome the publication of the Partnership Proposal as a significant milestone towards a European Partnership for Health Innovation.